Renal dosimetry in peptide radionuclide receptor therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 5, 2010, Pages 581-588

  Siegel, Jeffry A ^a   Stabin, Michael G ^b   Sharkey, Robert M ^c  

^a Nuclear Physics Enterprises   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

kidney dosimetry; radiation nephropathy; radionuclide therapy

Indexed keywords

RADIOISOTOPE;

ARTICLE; DOSE RESPONSE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; NEPHROTOXICITY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE FRACTIONATION;

DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KIDNEY; MODELS, THEORETICAL; PREDICTIVE VALUE OF TESTS; RADIATION INJURIES; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, PEPTIDE; RETROSPECTIVE STUDIES;

EID: 77958159117     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0805     Document Type: Article

References (33)

1. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl): 13S.
2. Rolleman EJ, Melis M, Valkema R, et al. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010;37:1018.
3. Bouchet LG, Bolch WE, Blanco HP, et al. MIRD Pamphlet No. 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 2003;44:1113.
4. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294.
5. Goitein M. The comparison of treatment plans. Semin Radiat Oncol 1992;2:246.
6. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679.
7. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a doseeffect relationship. J Nucl Med 2005;46(Suppl): 99S.
8. 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847.
9. Cremonesi M, Ferrari M, Bodei L, et al. Dosimetry in peptide receptor therapy: A review. J Nucl Med 2006;47:1467.
10. Rao DV, Howell RW. Time-dose-fractionation in radioimmunotherapy: Implications for selecting radionuclides. J Nucl Med 1993;34:1801.
11. Howell RW, Goddu SM, Rao DV. Application of the linearquadratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides. J Nucl Med 1994;35:1861.
12. Bigler RE. Dosimetry for evaluation of the biologic effects of radiation treatment using internally deposited radionuclides and labeled compounds. In: Cloutier RJ, Coffey JL, Snyder WS, et al. (eds.), Radiopharmaceutical Dosimetry Symposium, Proceedings of a Conference held at Oak Ridge, TN, April 26-29, 1976, HEW Publication (FDA) 76-8044, U. S. Department of Health, Education, and Welfare, 1976:221.
13. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD Pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med 2008;49:1884.
14. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538.
15. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023.
16. McAfee JG. Problems in evaluating the radiation dose for radionuclides excreted by the kidneys. In: Cloutier RJ, Edwards CL, Snyder WS (eds.), Medical Radionuclides: Radiation Dose and Effects. Oak Ridge, TN: U. S. Atomic Energy Commission, 1970:271.
17. Orton CG. Time-dose factors (TDFs) in brachytherapy. Br J Radiol 1974;47:603.
18. Niemierko A, Goitein M. Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. Radiother Oncol 1991;20:166.
19. 3-octreotate. J Nucl Med 2005;46:83S.
20. 3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm 2003;18:619.
21. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 2004;19:378.
22. Voit EO, Yi PN. Comparison of isoeffect relationships in radiotherapy. Bull Math Biol 1990;52:657.
23. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995;31:1249.
24. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109.
25. Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991;21:123.
26. Yorke ED. Modeling the effects of inhomogeneous dose distributions in normal tissues. Semin Radiat Oncol 2001;11:197.
27. Schultheiss TE. The controversies and pitfalls in modeling normal tissue radiation injury/damage. Semin Radiat Oncol 2001;11:210.
28. Baechler S, Hobbs RF, Prideaux AR, et al. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys 2008;35:1123.
29. Siegel JA. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: Practical aspects and limitations of red marrow dosimetry. Cancer Biother Radiopharm 2005;2:126.
30. Breitz H. Clinical aspects of radiation nephropathy. Cancer Biother Radiopharm 2004;19:359.
31. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm 2004;19:363.
32. Orton CG. Recent developments in time-dose modelling. Australas Phys Eng Sci Med 1991;14:57.
33. 111In-DTPA] octreotide. J Nucl Med 2004;45:1168.